Innovation Hub
We are not a discovery-stage drug company. Our innovation lives in three places: how we read the evidence, how we formulate, and how we make medicines easier for a kidney patient to live with for the next thirty years.
What innovation means here
01
We read the literature deeply in the areas we work. We do not promote outside the approved label - and we don't oversimplify what the evidence actually says. Our long-form articles are written by and with practicing nephrologists.
02
Double-strength tablets for pill-burden patients. Soft-gel sevelamer for tablet-averse elderly dialysis patients. The unsexy work of making a thirty-year medicine actually swallowable.
03
Pack design that supports adherence. Calendar packs for the post-transplant period. Caregiver counselling tools. The pieces that decide whether a prescription written today is still being taken in year ten.
Therapy-area insights
A growing library, published roughly monthly. Each piece anchors to current guidelines and peer-reviewed evidence. Intended for healthcare professionals.
Renal Nutrition
Updated KDOQI 2020 guidelines and recent meta-analyses position low-protein or very-low-protein diet supplemented with ketoanalogues as one of the few interventions shown to slow CKD progression and delay dialysis initiation.
Transplant
Inter-patient and intra-patient variability in tacrolimus exposure remains one of the strongest modifiable predictors of long-term graft outcomes. What the recent transplant literature tells us about formulation, monitoring frequency, and the practical clinic-side levers.
Transplant
ERLB301 / ERLB302 equivalence with MMF. The GI tolerability case and the conversion literature. Where MPA TDM adds value, and dose-reduction strategy in BK virus and CMV.
CKD-MBD
The choice of phosphate binder is no longer just a phosphate question. We revisit the calcification-attenuation data on non-calcium binders and what it means for binder selection in stage 4–5 CKD.
Hyperuricemia
Why allopurinol is not the default choice in Asian CKD patients, where febuxostat fits in the urate-lowering algorithm, and the dosing approach that balances efficacy with renal safety.
Gut–Kidney Axis
From indoxyl sulfate and p-cresyl sulfate biology to the clinical evidence around probiotic and synbiotic adjuncts in CKD - and what to actually do with it in 2026.
Full articles will be published progressively. To be notified, write to our Medical Information channel.
Collaborations
We work closely with practicing nephrologists, transplant surgeons and renal dieticians across India. Our Scientific Advisory Board challenges our positioning, sense-checks our content, and keeps our understanding of the discipline current.
We are open to academic partnerships, investigator-initiated studies, and clinical-collaborative work that helps the kidney patient. To discuss, write to our Medical Affairs team.